| 17.07 12:32 | dpa-AFX: *JOHNSON & JOHNSON NOW SEES FY ADJ OPERATIONAL EPS PRE-M&A $10.73; ADJ OPERATIONAL EPS $10.05 |
| 17.07 12:30 | dpa-AFX: *JOHNSON & JOHNSON Q2 ADJ OPERATIONAL SALES UP 6.5%; ADJ OPERATIONAL SALES, EXCL COVID-19 VACCINE, UP 7.1% |
| 17.07 12:29 | dpa-AFX: *JOHNSON & JOHNSON Q2 SALES UP 4.3% TO $22.4 BLN WITH OPERATIONAL GROWTH OF 6.6% |
| 17.07 12:28 | dpa-AFX: Johnson & Johnson Q2 Profit Decreases, But Beats Estimates |
| 17.07 12:23 | dpa-AFX: *JOHNSON & JOHNSON Q2 EPS $1.93 VS. $2.05 LAST YEAR |
| 17.07 12:04 | dpa-AFX: Johnson & Johnson Q2 24 Earnings Conference Call At 8:30 AM ET |
| 17.07 11:18 | dpa-AFX: ROUNDUP/Gericht zu Covid-Impfstoff: EU-Kommission gab zu wenig Infos |
| 17.07 11:18 | ROUNDUP/Gericht zu Covid-Impfstoff: EU-Kommission gab zu wenig Infos |
| 17.07 11:13 | dpa-AFX: ROUNDUP/Gericht zu Covid-Impfstoff: EU-Kommission gab zu wenig Infos |
| 17.07 05:26 | dpa-AFX: ORIC Enters Into Clinical Trial Collaboration And Supply Agreements With Bayer and J&J; Stock Up |
| 03.07 14:10 | dpa-AFX: Johnson & Johnson Announces Health Canada NOC For RYBREVANT Combination |
| 03.07 14:04 | dpa-AFX: *J&J : HEALTH CANADA AUTHORIZES RYBREVANT COMBINATION FOR EGFR EXON 20 NON-SMALL CELL LUNG CANCER |
| 02.07 13:51 | dpa-AFX: J&J Reports Positive Data From Phase 3 CARTITUDE-4 Study Of Carvykti In Multiple Myeloma |
| 02.07 13:35 | dpa-AFX: *JOHNSON & JOHNSON REPORTS POSITIVE PHASE 3 RESULTS FOR CARVYKTI IN RELAPSED MULTIPLE MYELOMA |
| 01.07 07:31 | dpa-AFX: Sandoz To Commercialize Samsung Bioepis' FDA Approved Biosimilar Pyzchiva In US |
| 28.06 17:14 | dpa-AFX: J&J: Rybrevant In Combination Gets Approval In Europe For First-Line Treatment Of NSCLC |
| 28.06 16:33 | dpa-AFX: *J&J : RYBREVANT COMBINATION APPROVED IN EUROPE FOR FIRST-LINE TREATMENT OF NSCLC |
| 28.06 13:58 | dpa-AFX: Janssen-Cilag Says CHMP Recommended Balversa For Urothelial Carcinoma |
| 28.06 13:37 | dpa-AFX: *JANSSEN CILAG : CHMP BACKS BALVERSA FOR ADVANCED UROTHELIAL CARCINOMA TREATMENT |
| 21.06 13:33 | dpa-AFX: *JOHNSON & JOHNSON CLOSES ACQUISITION OF PRIVATELY-HELD BIOTECHNOLOGY COMPANY PROTEOLOGIX |
|
|
